Tri Locum Partners LP: UNITED THERAPEUTICS CORP DEL (UTHR): Quarterly 13F Position History
As of Q1 2026, Tri Locum Partners LP reported 70,370 shares of UNITED THERAPEUTICS CORP DEL (UTHR), worth $41.7M and representing 5.9% of its 13F equity book. Quarter-over-quarter share count change: 50,551 (-41.8%) . The position first appeared in Q3 2021 and has been disclosed across 19 13F-HR filings in Pactolio's tracked window.
- 70,370Shares Held (Latest Filing)
- $41.7MReported Market Value (Latest Filing)
- 5.9%Portfolio Weight (% of 13F Equity Book)
- 50,551Quarter-over-Quarter Share Change
- -$17.2MQuarter-over-Quarter Value Change
- 122,187Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 19 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 70,370 | 50,551 | -41.8% | $41.7M | 5.9% | $593.0 |
| Q4 2025 | 120,921 | 1,266 | -1.0% | $58.9M | 7.7% | $487.3 |
| Q3 2025 | 122,187 | +122,187 | — | $51.2M | 11.8% | $419.2 |
| Q2 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2024 | 0 | 54,926 | -100.0% | $0 | 0.0% | — |
| Q3 2024 | 54,926 | +4,826 | +9.6% | $19.7M | 4.7% | $358.4 |
| Q2 2024 | 50,100 | +50,100 | — | $16.0M | 4.0% | $318.6 |
| Q1 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2022 | 0 | 45,904 | -100.0% | $0 | 0.0% | — |
| Q4 2021 | 45,904 | +13,053 | +39.7% | $9.9M | 4.0% | $216.1 |
| Q3 2021 | 32,851 | — | — | $6.1M | 2.8% | $184.6 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Tri Locum Partners LP first disclose a UTHR position in 13F-HR filings?
Tri Locum Partners LP first reported UNITED THERAPEUTICS CORP DEL (UTHR) on its 13F-HR filing for the period ending 2021-09-30 (Q3 2021). The position has appeared on 19 reported quarters within Pactolio's tracked window.
What was Tri Locum Partners LP's most recent quarter-over-quarter share-count change in UTHR?
Between Q4 2025 and Q1 2026, Tri Locum Partners LP reduced its UTHR position by 50,551 shares (-41.8%), leaving 70,370 shares at a market value of $41.7M.
Does the implied price-per-share represent Tri Locum Partners LP's cost basis in UTHR?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.